WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceut...( NEW YORK Aug. 8 /- On August 7 J....),Health

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- On August 7, J. J. Finkelstein, Chief Executive Officer of RegeneRx Biopharmaceuticals (Amex: RGN) updated the investment community in an all-new interview with http://www.wallst.net. Topics covered in the interview include RegeneRx Biopharmaceuticals' clinical trials, market potential, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About RegeneRx Biopharmaceuticals:

RegeneRx, headquartered in Bethesda, Maryland, is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. The Company is currently sponsoring five clinical trials for dermal wound healing, ophthalmic wound healing, and cardiovascular protection and regeneration after heart attack.

RegeneRx utilizes an outsourcing business model in order to effectively control costs while focusing on clinical development of its drug candidates. This model is used for research and development, manufacturing, drug formulation and clinical trials, as well as for other functions critical to its mission and enhances RegeneRx's ability to allocate resources rapidly to different projects without having to invest in infrastructure.

For more information about this Company, please visit http://www.regenerx.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Dire
'/>"/>

SOURCE Financial Filings Corp. Copyright©2007 PR Newswire.

0 GOOD